ClariVest Asset Management’s Kyntra Bio KYNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-2,279
Closed -$1.98M 777
2021
Q1
$1.98M Sell
2,279
-52
-2% -$55.4K 0.07% 209
2020
Q4
$2.16M Sell
2,331
-893
-28% -$939K 0.07% 207
2020
Q3
$3.31M Buy
3,224
+1,620
+101% +$1.74M 0.11% 150
2020
Q2
$1.63M Buy
1,604
+668
+71% +$620K 0.04% 262
2020
Q1
$813K Sell
936
-2
-0.2% -$1.99K 0.02% 328
2019
Q4
$1.01M Sell
938
-624
-40% -$637K 0.02% 354
2019
Q3
$1.44M Sell
1,562
-20
-1% -$22K 0.03% 300
2019
Q2
$1.79M Sell
1,582
-16
-1% -$17.5K 0.04% 262
2019
Q1
$2.17M Sell
1,598
-121
-7% -$164K 0.04% 303
2018
Q4
$1.99M Buy
1,719
+665
+63% +$747K 0.04% 309
2018
Q3
$1.6M Sell
1,054
-29
-3% -$44.7K 0.03% 355
2018
Q2
$1.7M Sell
1,083
-28
-3% -$36.5K 0.03% 364
2018
Q1
$1.28M Buy
1,111
+8
+0.7% +$10.5K 0.02% 397
2017
Q4
$1.31M Sell
1,103
-519
-32% -$651K 0.02% 392
2017
Q3
$2.18M Sell
1,622
-1,727
-52% -$1.82M 0.05% 276
2017
Q2
$2.7M Sell
3,349
-2
-0.1% -$1.39K 0.07% 248
2017
Q1
$2.06M Buy
+3,351
New +$2.04M 0.05% 273

Other funds holding KYNB

ClariVest Asset Management's KYNB Position: Q2 2021 in Review

ClariVest Asset Management sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 2,279 shares — an estimated $1.98M sold.

ClariVest Asset Management first reported a position in KYNB in Q1 2017 and held it in 17 quarters. The position peaked at $3.31M in Q3 2020. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

  • ClariVest Asset Management reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 2,279 Kyntra Bio shares in Q2 2021, an estimated $1.98M.
  • ClariVest Asset Management first reported a position in Kyntra Bio in Q1 2017 and held it in 17 quarters.
  • ClariVest Asset Management's Kyntra Bio position peaked at $3.31M in Q3 2020.
  • 174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on ClariVest Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.